Related Experiment Video

Updated: Jul 1, 2026

High-Throughput Cellular Profiling of Targeted Protein Degradation Compounds Using HiBiT CRISPR Cell Lines
05:33

High-Throughput Cellular Profiling of Targeted Protein Degradation Compounds Using HiBiT CRISPR Cell Lines

Published on: November 9, 2020

Eyes Toward the Clinic: Selective Inhibition and Degradation Approaches to Bromodomain-Containing Proteins

Cole R Scholtz1, William C K Pomerantz1

  • 1Department of Chemistry, University of Minnesota - Twin Cities, Minneapolis, Minnesota, USA.

Chembiochem : a European Journal of Chemical Biology
|June 30, 2026
PubMed

Insights

Bromodomain inhibitors and degraders offer new therapeutic strategies by targeting epigenetic regulators. This review explores their clinical progress and molecular mechanisms for treating diseases.

Area of Science:

  • Epigenetics and Molecular Biology
  • Drug Discovery and Development

Background:

  • Bromodomain-containing proteins are key epigenetic regulators that control gene expression.
  • Bromodomain and extra-terminal (BET) family proteins are significant drug targets due to their role in gene regulation.
  • Targeting bromodomains via inhibition or degradation is a promising therapeutic strategy.

Purpose of the Study:

  • To review current inhibition and targeted protein degradation approaches for bromodomain-containing proteins.
  • To discuss the clinical progress and molecular mechanisms of BET inhibitors and degraders.
  • To summarize therapeutic strategies for both BET and non-BET bromodomain proteins.

Main Methods:

  • Literature review of current research on bromodomain-targeting therapies.
  • Analysis of clinical trial data for BET inhibitors and degraders.
  • Examination of molecular mechanisms underlying inhibition and degradation strategies.

Main Results:

  • Selective inhibition and degradation of BET proteins show diverse biological effects and clinical potential.
  • BET inhibitors have advanced to Phase III trials, with degraders emerging as clinical candidates.
  • Approaches for non-BET bromodomain proteins are also under investigation.

Conclusions:

  • Bromodomain-targeted inhibition and degradation represent a rapidly advancing field in drug discovery.
  • Understanding molecular mechanisms and clinical progress is crucial as the first bromodomain therapeutic nears approval.
  • These modalities offer new avenues for treating diseases driven by aberrant gene expression.
Keywords:
PROTACbromodomainclinical trialsepigenetics

More Related Videos

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

The Development and Application of Biophysical Assays for Evaluating Ternary Complex Formation Induced by Proteolysis Targeting Chimeras (PROTACS)07:22

The Development and Application of Biophysical Assays for Evaluating Ternary Complex Formation Induced by Proteolysis Targeting Chimeras (PROTACS)

Published on: January 12, 2024

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Conserved Binding Sites01:49

Conserved Binding Sites

Many proteins’ biological role depends on their interactions with their ligands, small molecules that bind to specific locations on the protein known as ligand-binding sites. Ligand-binding sites are often conserved among homologous proteins as these sites are critical for protein function.
Binding sites are often located in large pockets, and if their location on a protein’s surface is unknown, it can be predicted using various approaches. The energetic method computationally analyses the...
Covalently Linked Protein Regulators02:04

Covalently Linked Protein Regulators

Proteins can undergo many types of post-translational modifications, often in response to changes in their environment. These modifications play an important role in the function and stability of these proteins. Covalently linked molecules include functional groups, such as methyl, acetyl, and phosphate groups, and also small proteins, such as ubiquitin. There are around 200 different types of covalent regulators that have been identified.
These groups modify specific amino acids in a protein.
Ligand Binding and Linkage00:49

Ligand Binding and Linkage

Allosteric proteins have more than one ligand binding site; the binding of a ligand to any of these sites influences the binding of ligands to the other sites. When a protein is allosteric, its binding sites are called coupled or linked.  In the case of enzymes, the site that binds to the substrate is known as the active site and the other site is known as the regulatory site. When a ligand binds to the regulatory site, this leads to conformational changes in the protein that can influence the...